Brief: Alligator And Orion Develop Option Under 2021 Collaboration And License Agreement
26/04/2024 08:51
April 26 (Reuters) - Alligator Bioscience ATORX.ST :
* ALLIGATOR BIOSCIENCE AND ORION CORPORATION ANNOUNCE
EXERCISE OF
DEVELOPMENT OPTION UNDER 2021 IMMUNO-ONCOLOGY RESEARCH
COLLABORATION AND LICENSE AGREEMENT
* ALLIGATOR BIOSCIENCE AB - EXERCISE OF THIS DEVELOPMENT
OPTION
TRIGGERS AN UNDISCLOSED MILESTONE PAYMENT TO ALLIGATOR
Source text for Eikon: ID:nMFN8MFN2D
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Orion
See all newsBrief: Flashlight Capital Partners A Shareholder Of Orion Corp. Today Sent An Open Letter To Orion's Board With Five Requests
Brief: Orion To Spend 69 Billion Won On Dividend
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Brief: Orion Corp 2025 Operating Profit 558.2 Billion Won, Up 2.7% From Year Earlier
Brief: Orion Corp To Invest 228 Billion Won In Building A Factory In Jincheon County, South Korea